Literature DB >> 16489174

Do we need to measure total serum IgA to exclude IgA deficiency in coeliac disease?

D Sinclair1, M Saas, A Turk, M Goble, D Kerr.   

Abstract

BACKGROUND: Screening for IgA deficiency in patients with coeliac disease is essential because of the increased incidence of IgA deficiency associated with the disease, which usually relies on the estimation of IgA levels in each case. AIM: To devise a method of excluding IgA deficiency without measuring total serum IgA in each case.
MATERIALS AND METHODS: The optical density readings on enzyme-linked immunosorbent assay (ELISA) of 608 routine samples received for tissue transglutaminase (TTG) antibody testing for coeliac disease were compared with their total IgA concentrations. Dilution experiments were also carried out to ensure linear relationships between optical density on ELISA and IgA concentrations and to compare the sensitivities for TTG and endomysium antibodies in TTG-positive samples. RESULTS AND DISCUSSION: A clear relationship was shown between total IgA concentration and TTG optical density readings by ELISA. To ensure a positive TTG result if antibodies are present, it was possible to recommend an optical density level above which all samples have sufficient IgA. Samples with optical density <0.05 should be investigated further by estimating total IgA and, if low, samples should be subjected to immunofluorescence microscopy testing for IgA and IgG endomysium antibodies.
CONCLUSIONS: An easier, more cost-effective and practical way of excluding IgA deficiency in the investigation on coeliac disease is reported.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16489174      PMCID: PMC1860425          DOI: 10.1136/jcp.2005.031864

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  IgG(1) antiendomysium and IgG antitissue transglutaminase (anti-tTG) antibodies in coeliac patients with selective IgA deficiency. Working Groups on Celiac Disease of SIGEP and Club del Tenue.

Authors:  F Cataldo; D Lio; V Marino; A Picarelli; A Ventura; G R Corazza
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

2.  IgA antibodies to human tissue transglutaminase: audit of routine practice confirms high diagnostic accuracy.

Authors:  P G Hill; J M Forsyth; D Semeraro; G K T Holmes
Journal:  Scand J Gastroenterol       Date:  2004-11       Impact factor: 2.423

3.  Use of low concentrations of human IgA anti-tissue transglutaminase to rule out selective IgA deficiency in patients with suspected celiac disease.

Authors:  Eloy Fernández; Carlos Blanco; Sara García; Angeles Dieguez; Sabino Riestra; Luis Rodrigo
Journal:  Clin Chem       Date:  2005-03-24       Impact factor: 8.327

4.  Prevalence of coeliac disease in Northern Ireland.

Authors:  S D Johnston; R G Watson; S A McMillan; J Sloan; A H Love
Journal:  Lancet       Date:  1997-11-08       Impact factor: 79.321

5.  Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Authors:  Ivor D Hill; Martha H Dirks; Gregory S Liptak; Richard B Colletti; Alessio Fasano; Stefano Guandalini; Edward J Hoffenberg; Karoly Horvath; Joseph A Murray; Mitchell Pivor; Ernest G Seidman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-01       Impact factor: 2.839

6.  Immunoglobulin G (IgG) anti-tissue transglutaminase antibodies used as markers for IgA-deficient celiac disease patients.

Authors:  Ingrid Dahlbom; Martin Olsson; Nahal Kazemi Forooz; Anders G Sjöholm; Lennart Truedsson; Tony Hansson
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

7.  Diagnostic accuracy of ten second-generation (human) tissue transglutaminase antibody assays in celiac disease.

Authors:  Britta Van Meensel; Martin Hiele; Ilse Hoffman; Severine Vermeire; Paul Rutgeerts; Karel Geboes; Xavier Bossuyt
Journal:  Clin Chem       Date:  2004-09-23       Impact factor: 8.327

8.  Selective IgA deficiency and coeliac disease.

Authors:  P Collin; M Mäki; O Keyriläinen; O Hällström; T Reunala; A Pasternack
Journal:  Scand J Gastroenterol       Date:  1992-05       Impact factor: 2.423

9.  Is immunoglobulin A anti-tissue transglutaminase antibody a reliable serological marker of coeliac disease?

Authors:  Robert J Lock; Susan Stevens; Maxton C L Pitcher; David J Unsworth
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-05       Impact factor: 2.566

10.  Mass screening for coeliac disease using antihuman transglutaminase antibody assay.

Authors:  A Tommasini; T Not; V Kiren; V Baldas; D Santon; C Trevisiol; I Berti; E Neri; T Gerarduzzi; I Bruno; A Lenhardt; E Zamuner; A Spanò; S Crovella; S Martellossi; G Torre; D Sblattero; R Marzari; A Bradbury; G Tamburlini; A Ventura
Journal:  Arch Dis Child       Date:  2004-06       Impact factor: 3.791

View more
  4 in total

1.  Implementation of National Institute for Health and Care Excellence (NICE) guidance to measure immunoglobulin A with all coeliac screens: can an affordable solution be devised?

Authors:  D J Mac Lochlainn; R Hira-Kazal; H Varney; J Maher
Journal:  Clin Exp Immunol       Date:  2017-05-19       Impact factor: 4.330

Review 2.  Selective IgA deficiency in autoimmune diseases.

Authors:  Ning Wang; Nan Shen; Timothy J Vyse; Vidya Anand; Iva Gunnarson; Gunnar Sturfelt; Solbritt Rantapää-Dahlqvist; Kerstin Elvin; Lennart Truedsson; Bengt A Andersson; Charlotte Dahle; Eva Ortqvist; Peter K Gregersen; Timothy W Behrens; Lennart Hammarström
Journal:  Mol Med       Date:  2011-08-04       Impact factor: 6.354

Review 3.  Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper.

Authors:  Cristina M A Jacob; Antonio C Pastorino; Kristine Fahl; Magda Carneiro-Sampaio; Renato C Monteiro
Journal:  J Clin Immunol       Date:  2008-01-17       Impact factor: 8.317

4.  ACG clinical guidelines: diagnosis and management of celiac disease.

Authors:  Alberto Rubio-Tapia; Ivor D Hill; Ciarán P Kelly; Audrey H Calderwood; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2013-04-23       Impact factor: 10.864

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.